Welcome to Financial Freestyle. I'm Ross Mack and this is sponsored by Vanguard. Welcome to Financial Freestyle here on Yahoo Finance and I'm your host Ross Mack. Look, no matter where you are in your journey when it comes to building wealth, you can never stop learning and that's why I am speaking to some of the most influential people in the world of finance. And today is no different as I'm speaking to the chief editor of Investopedia, Mr.. Caleb Silver. Caleb, my man, how you doing, bro? It is so good t ...

Matt Orton, Raymond James chief market strategist, joins 'Power Lunch' to discuss the strategist's thoughts on equity investors, tactical advice and much more. ...

Which matters more to you as a stock investor: ...

Joining us this morning is Rushier Chararma, Rockefeller International Chairman for his outlook. Rousier, it's great to have you back. I wonder what you make of this um strong and steady resilience after that brief mild decline on Friday.Well, I think the markets over time have learned to brush aside geopolitical tensions. In fact, we've done some research on this and what it shows is this is Carl that if you look at since 1950 uh the 25 most significant geopolitical shocks around the world, the S&P 500 ten ...

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics have formed a strategic investor relations partnership with astr partners to enhance their visibility and investor engagement at a critical juncture in their development [1][2][3] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [4] - The company is advancing NRX-101, which has received FDA designation as an investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression, and plans to file for Accelerated Approval [4] - NRx has filed an Abbreviated New Drug Application (ANDA) for NRX-100, a preservative-free IV ketamine, and is also pursuing a New Drug Application for the treatment of suicidal depression [5] HOPE Therapeutics Overview - HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals, focused on building a network of interventional psychiatry clinics that provide ketamine and transcranial magnetic stimulation (TMS) therapies [6] - The company aims to offer lifesaving therapies for patients with suicidal depression and related disorders, supported by a digital therapeutic-enabled platform [6] Strategic Partnership - The partnership with astr partners is expected to leverage their extensive experience in biotech investor relations and relationships with specialist investors to enhance NRx and HOPE's market presence [2][3] - The investor relations program will include investor targeting, message development, earnings preparation, conference support, and proactive engagement [3]

NEW YORK, June 16, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152955&from=4CLASS PERIOD: July 3, 202 ...

J P M O R G A N Global Markets Strategy 11 June 2025 This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. Krutik P Mehta Flows & Liquidity The share of retail in US equity trading subsided during Feb/Mar Global Markets Strategy Nikolaos Panigirtzoglou AC (44-20) ...

Market Reaction - Stock futures on Wall Street experienced significant declines, with the Dow Jones Industrial Average falling 453 points (1.05%) to 42,863, S&P 500 dropping 57.50 points (0.95%) to 5,992, and Nasdaq futures declining 273.50 points (1.23%) to 21,885 [1][7] - Oil prices surged, with Brent crude increasing over 7% to $74.28 per barrel, driven by fears of supply disruptions due to escalating violence in the Middle East [3][14] Geopolitical Developments - Israeli airstrikes targeted senior military figures and nuclear facilities in Iran, resulting in the deaths of several high-ranking officials, including military chief Mohammad Hossein Bagheri and Revolutionary Guard commander Hossein Salami [3][4] - Iran retaliated by launching around 100 drones toward Israel, escalating tensions further [4] Investor Sentiment - Investors sought safety amid the turmoil, leading to a rise in US Treasury bonds, with the 10-year yield increasing to 4.369% [5] - The WSJ Dollar Index rose 0.53% to 95.15, indicating renewed demand for the US dollar, while the Cboe Volatility Index (VIX) surged above 21, reflecting increased investor anxiety [6] Broader Market Impact - Gold prices reached a near two-month high, while auto stocks faced pressure following comments from former President Trump regarding potential import levies [8] - European and Asian stock markets also declined, contributing to a souring market mood [9] International Response - The International Atomic Energy Agency reported that Iran's Isfahan nuclear site was unaffected by the strikes, with no increases in radiation levels detected at the Natanz site [9] - UN Secretary-General Antonio Guterres called for restraint from both Iran and Israel, emphasizing the need to avoid further conflict in the region [12][13]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Vestis Corporation (NYSE:VSTS) securities between May 2, 2024, and May 6, 2025, due to allegations of misleading statements regarding customer growth and business performance [1][2]. Allegations - The complaint alleges that Vestis Corporation misled investors by failing to disclose its inability to execute strategic initiatives aimed at improving customer experience and onboarding, which were expected to drive new customer growth and revenue [2]. - It is claimed that these misleading statements led to investors purchasing Vestis securities at artificially inflated prices [2]. Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year, and provided third-quarter guidance that was significantly below market expectations [3]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [3]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Participation - Shareholders interested in participating in the class action against Vestis Corporation must file a motion for lead plaintiff by August 8, 2025 [4]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [4].

All right. So, you say retail investors, they're buying on the rumor here. Uh, again, we thought this robo tax thing was going to happen today at first and then Elon Musk says it's not going to happen for another week and a half or so.Is there potential for retail investors here to sell the news if this isn't as impressive as many people believe or is there kind of a cult of Elon Musk here. We're going to continue to buy this stock in your opinion. I think both statements are true.uh in the past we have see ...